Contact | 
Print version | 
PDF version | 
Send article | 
RSS-Feed
DSM invests in innovative treatment against infectious diseases
07 Mar 2008 -
DSM Venturing, the corporate venturing unit of Royal DSM N.V., announced that it has made an equity investment in the Dutch company IQ Therapeutics B.V. The company develops antibody based products for biodefense and for the prevention and treatment of infectious diseases. DSM Venturing will hold a significant minority share in IQ Therapeutics.
The investment underlines DSM's position as a partner of choice for the pharma industry and expands the already existing relationship between both companies. IQ Therapeutics is a PER.C6® License Holder with DSM Biologics and Crucell for the production of its monoclonal antibodies.
In addition to the PER.C6® license and the new equity investment, IQ Therapeutics and DSM Biologics have a manufacturing agreement in place for process development, pilot manufacturing and GMP manufacturing of IQ Therapeutics' anti-anthrax antibody product. This product has been developed with IQ Therapeutics' proprietary technology for the generation of fully human antibodies from the blood of vaccinated donors.
The investment in IQ Therapeutics fits in DSM's strategy to fortify its presence in the biopharmaceutical market. This is the fastest growing market segment of the pharmaceutical market and is expected to more than triple in the next ten years.
This investment brings the total number of current company participations of DSM Venturing to 21. Venturing forms an integral part of DSM's open innovation approach, focused on teaming up with innovative players all over the world. The company has earmarked up to EUR 200 million for venturing investments until 2012.
Top